| Field | Specification |
|---|---|
| Target | |
| Alternative names | Cholesterol 7-alpha-monooxygenase;1.14.13.17;CYPVII;Cholesterol 7-alpha-hydroxylase;Cytochrome P450 7A1;CYP7A1;CYP7; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human CYP7A1 recombinant protein (Position: M301-L504). Human CYP7A1 shares 85.2 % and 83.3% amino acid (aa) sequence identity with mouse and rat CYP7A1, respectively. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets cytochrome P450 7A1 (gene CYP7A1) in human and rat samples and is validated for flow cytometry and Western blot. The predicted molecular weight is 57.7 kDa, and the supplier reports an observed band at about 58 kDa.
Cholesterol 7α-hydroxylase (CYP7A1) is a liver cytochrome P450 that catalyzes the first and rate-limiting step of the classic bile acid synthesis pathway. Its expression is tightly controlled by bile acids through FXR and FGF19 feedback, so it is a key point of control for cholesterol elimination and is studied in lipid metabolism and liver disease.
| Target | Cytochrome P450 7A1 (gene CYP7A1; UniProt P22680, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 57.7 kDa |
| Observed MW | 58 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL (Human, Rat) |
|---|---|
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
Samples with a confirmed band (WB): human HeLa cells, human K562 cells, rat RH35 whole clel.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with a confirmed signal (flow cytometry): SiHa cells.
Immunogen
Recombinant human CYP7A1 fragment (Met301–Leu504), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human and rat. UniProt places cytochrome P450 7A1 in the endoplasmic reticulum membrane and microsome membrane. Tissue expression noted by UniProt (human): Detected in liver. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Tao-tao Wang et al. (2023) QiShenYiQi pill inhibits atherosclerosis by promoting TTC39B-LXR mediated reverse cholesterol transport in liver. Phytomedicine. 10.1016/j.phymed.2023.155192
Hong-Liu Jin et al. (2023) Quercetin 7-rhamnoside protects against alpha-naphthylisothiocyanate (ANIT)-induced in cholestatic hepatitis rats by improving biliary excretion and inhibiting inflammatory responses. Frontiers in Pharmacology. 10.3389/fphar.2022.1116257
Kexin Xiao et al. (2024) Protective effects and mechanism of Sangyu granule on acetaminophen-induced liver injury in mice. Journal of Ethnopharmacology. 10.1016/j.jep.2024.118282
Yang Liu et al. (2019) Fish oil alleviates circadian bile composition dysregulation in male mice with NAFLD. Journal of Nutritional Biochemistry. 10.1016/j.jnutbio.2019.03.005
Lu Xu et al. (2023) Zhuyu Pill Alleviates Nonalcoholic Fatty Liver Disease by Regulating Bile Acid Metabolism through the Gut–Liver Axis. ACS Omega. 10.1021/acsomega.3c01955
Caitlin Vonderohe et al. (2021) Tissue-specific mechanisms of bile acid homeostasis and activation of FXR-FGF19 signaling in preterm and term neonatal pigs. American Journal of Physiology-Gastrointestinal and Liver Physiology. 10.1152/ajpgi.00274.2021
Qichao Chen et al. (2019) Fucoidan and galactooligosaccharides ameliorate high-fat diet–induced dyslipidemia in rats by modulating the gut microbiota and bile acid metabolism. Nutrition. 10.1016/j.nut.2019.03.001
Guinan Xie et al. (2026) Jiangzhi ruanmai recipe alleviates atherosclerosis in ApoE−/− mice by regulating cholesterol metabolism involved in gut microbiota remodeling. Frontiers in Cardiovascular Medicine. 10.3389/fcvm.2026.1834983
